MYLAN ANNOUNCES SUPPLY AGREEMENT WITH ORTHO-MCNEIL ON OXYBUTYNIN

Mylan Laboratories Inc. (NYSE:MYL) announced today that its subsidiary, Mylan Pharmaceuticals Inc., has entered into two agreements with Ortho-McNeil Pharmaceutical, Inc. and Alza Corporation relating to oxybutynin chloride extended release tablets, a generic version of DITROPAN XL(R) oxybutynin chloride extended release tablets. Mylan has received tentative approval and is currently awaiting final approval from the United States Food and Drug Administration (FDA) for its 5 and 10 mg strengths of Oxybutynin.

Biotech Intelligence (http://www.biotech-intelligence.com/html/html/9f84af2e386e5d4d9c4efa21dbf46ff1.html)